Adial Pharmaceuticals, Inc. (ADIL): R&D Expense
$2.62M
Year ended 2025-12-31
+10.3%
3-year compound annual growth
-14.9%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.62M | -18.9% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $3.23M | +154.9% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $1.27M | -35.0% | 2025-03-04, From 2023-01-01 |
| 2022-12-31 | $1.95M | -76.8% | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | $8.40M | +43.4% | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | $5.85M | +47.6% | 2022-03-28, From 2020-01-01 |
| 2019-12-31 | $3.97M | +976.3% | 2021-03-22, From 2019-01-01 |
| 2018-12-31 | $368.5K | +102.3% | 2020-03-20, From 2018-01-01 |
| 2017-12-31 | $182.1K | n/a | 2019-02-19, From 2017-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Adial Pharmaceuticals, Inc. (ADIL) | 2025-12-31 | $2.62M | -18.9% |
| Kairos Pharma, Ltd. (KAPA) | 2025-12-31 | $2.13M | +415.7% |
| OS Therapies Inc (OSTX) | 2025-12-31 | $16.36M | +476.3% |
| Vyome Holdings, Inc (HIND) | 2025-12-31 | $588.3K | +106.1% |
| Serina Therapeutics, Inc. (SER) | 2025-12-31 | $13.15M | +75.9% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $122.0K | +3.4% |
| GeoVax Labs, Inc. (GOVX) | 2025-12-31 | $18.12M | -23.6% |
| Matinas BioPharma Holdings, Inc. (MTNB) | 2025-12-31 | $85.0K | -99.3% |
| Greenwich LifeSciences, Inc. (GLSI) | 2025-12-31 | $17.22M | +11.2% |
Compare ADIL, KAPA, OSTX, HIND side by side · Screen every company in Pharmaceutical Preparations ↗